MedTrace Logo

A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis

NCT00302445 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2007-07-13

No results posted yet for this study

Summary

An open label, single arm study to evaluate the study and efficacy of efalizumab in combination with NB-UVB. Weeks 1-12 efalizumab will be administered once a week in combination with NB-UVB three times per week. Weeks 13-24 efalizumab monotherapy will continue. Weeks 25-36 subjects will be followed for safety.

Subjects with moderate to severe plaque psoriasis often require more than one therapy to treat their disease. Because of the different mechanisms of action, it is thought that combined efalizumab and NB-UVB may be more effective and have a more rapid onset than either treatment alone.

Conditions

Interventions

DRUG

Efalizumab

DEVICE

Narrow Band Phototherapy

Sponsors & Collaborators

  • Dermatology Associates, PLLC

    collaborator UNKNOWN

  • Genentech, Inc.

    collaborator INDUSTRY

  • Derm Research, PLLC

    lead OTHER

Principal Investigators

  • Leon H Kircik, MD · Derm Research, PLLC

  • Bernard S Goffe, MD · Dermatology Associates, PLLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-03-31
Completion
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00302445 on ClinicalTrials.gov